Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Glucose Metabolism in Relation to Schizophrenia and Antipsychotic Drug Treatment

Glucose Metabolism in Relation to Schizophrenia and Antipsychotic Drug Treatment It has been reported in the earlier literature that many patients with psychoses had abnormalities in glucose metabolism as revealed by glucose tolerance testing. This observation is reinforced by the fact that the schizophrenic population appears to have about a 2–3-fold increased risk for Type II diabetes mellitus. However, some uncertainty remains about the relative risk value because there have been numerous case reports of patients who developed hyperglycemia and even Type II diabetes apparently as a consequence of treatment with antipsychotic drugs. Schizophrenic patients with abnormal glucose metabolism have a higher prevalence of drug-induced tardive dyskinesia than patients with a normal glucose profile. Treatment with the new atypical antipsychotics has a much lower risk of movement disorders; however, weight gain, hyperglycemia, and diabetes are emerging as significant side effects. Because glucose is essential for energy metabolism in neurons, any change in the effective glucose levels in brain that result from drug therapy may have significant clinical implications. It is not clear whether the glycemic state of schizophrenics contributes to their psychotic symptoms or modulates the incidence of drug side effects. Basic research shows that the drugs which cause hyperglycemia in patients appear to inhibit neuronal glucose transport which may partly explain their effects. This paper reviews the relevant literature in a preliminary attempt to understand the implications of such clinical findings in the light of basic research. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Clinical Psychiatry Springer Journals

Glucose Metabolism in Relation to Schizophrenia and Antipsychotic Drug Treatment

Download PDF
11 pages

Loading next page...
 
/lp/springer-journals/glucose-metabolism-in-relation-to-schizophrenia-and-antipsychotic-drug-vWqeTFozVv
Publisher
Springer Journals
Copyright
Copyright © 2001 by American Academy of Clinical Psychiatrists
Subject
Medicine & Public Health; Neurology; Psychiatry; Psychopharmacology
ISSN
1040-1237
eISSN
1573-3238
DOI
10.1023/A:1016671725396
Publisher site
See Article on Publisher Site

Abstract

It has been reported in the earlier literature that many patients with psychoses had abnormalities in glucose metabolism as revealed by glucose tolerance testing. This observation is reinforced by the fact that the schizophrenic population appears to have about a 2–3-fold increased risk for Type II diabetes mellitus. However, some uncertainty remains about the relative risk value because there have been numerous case reports of patients who developed hyperglycemia and even Type II diabetes apparently as a consequence of treatment with antipsychotic drugs. Schizophrenic patients with abnormal glucose metabolism have a higher prevalence of drug-induced tardive dyskinesia than patients with a normal glucose profile. Treatment with the new atypical antipsychotics has a much lower risk of movement disorders; however, weight gain, hyperglycemia, and diabetes are emerging as significant side effects. Because glucose is essential for energy metabolism in neurons, any change in the effective glucose levels in brain that result from drug therapy may have significant clinical implications. It is not clear whether the glycemic state of schizophrenics contributes to their psychotic symptoms or modulates the incidence of drug side effects. Basic research shows that the drugs which cause hyperglycemia in patients appear to inhibit neuronal glucose transport which may partly explain their effects. This paper reviews the relevant literature in a preliminary attempt to understand the implications of such clinical findings in the light of basic research.

Journal

Annals of Clinical Psychiatry – Springer Journals

Published: Oct 22, 2004

References

  • Basic Neurochemistry
    Sokoloff, L
  • Decreased cognitive function in aging non-insulin dependent diabetic patients
    Perlmutter, LC; Hakami, MK; Hodgson-Harrington, C; Ginsberg, J; Katz, J; Singer, DE; Nathan, DM
  • The impact of diabetes on the CNS
    McCall, AL
  • Pathophysiology of central nervous system complications in diabetes mellitus
    Mooradian, AD
  • Hypoglycemia in children with diabetes: Incidence, counterregulation and cognitive dysfunction
    Davis, EA; Jones, TW
  • Ahyperglycemic factor in the urine of so-called schizophrenics
    Meduna, LJ; Vaichulis, JA
  • Glucose tolerance in chronic schizophrenia and senile states
    Simon, W; Garvey, JT
  • Carbohydrate metabolism in brain disease. II. Glucose metabolism in schizophrenic, manic-depressive, and involutional psychoses
    Henneman, DH; Altschule, MD; Goncz, RM
  • Glucose tolerance curves in neuropsychiatric patients
    Balter, AM
  • Glucose-insulin metabolism in chronic schizophrenia
    Brambilla, F; Guastalla, A; Guerrini, A; Riggi, F; Rovere, C; Zanoboni, A; Zanoboni-Muciaccia, W
  • A survey for unknown diabetics in a mental hospital. II. Men from age fifty
    Waitzkin, L
  • A survey for unknown diabetics in a mental hospital. I. Men under age fifty
    Waitzkin, L
  • The methodical use of hypoglycemia in the treatment of psychoses
    Sakel, M
  • Results of insulin and epinephrine tolerance tests in schizophrenic patients and in normal subjects
    Freeman, H; Looney, JM; Hoskins, RG; Dyer, CG
  • Delayed action of insulin in schizophrenia
    Braceland, FJ; Meduna, LJ; Vaichulis, JA
  • A study of blood sugar response to insulin injection in schizophrenia
    Franzen, G; Nilsson, L
  • The positive correlation between insulin resistance and duration of hospitalization in schizophrenia
    Schimmelbusch, W; Mueller, P; Sheps, J
  • Glycemic effects of chlorpromazine in the mouse, hamster and rat
    Norman, D; Hiestand, WA
  • Some actions of chlorpromazine
    Ryall, RW
  • Changes in glucose synthesis and utilization in rats treated with chlorpromazine
    Chagovets, RV; Shtutman, TM
  • Chlorpromazine and glucose metabolism
    Jori, A; Bernardi, D; Garattini, S
  • Chlorpromazine in malignant insulinoma
    Lambert, AE; Henquin, JC; Orci, LO
  • Chlorpromazine in the treatment of endogenous organic hyperinsulinism
    Federspil, G; Casara, D; Stauffacher, W
  • Hyperglycemia and glycosuria following chlorpromazine therapy
    Hiles, BW
  • Phenothiazine derivatives and glucose metabolism
    Arneson, GA
  • Phenothiazines and diabetes in hospitalized women
    Thonnard-Neumann, E
  • Effect of chlorpromazine on blood glucose and plasma insulin in man
    Erle, G; Basso, M; Federspil, G; Sicolo, N; Scandellari, C
  • Nonketotic hyperglycemia associated with loxapine and amoxapine: Case report
    Tollefson, G; Lesar, T
  • Weight gain associated with neuroleptic medication: A review
    Stanton, JM
  • Antipsychotic-induced weight gain: A comprehensive research synthesis
    Allison, DB; Mentore, JL; Heo, M; Chandler, LP; Cappelleri, JC; Infante, MC; Weiden, PJ
  • Severe hyperglycemia associated with high doses of clozapine
    Kamran, A; Doraiswamy, PM; Jane, JL
  • Serum triglyceride levels in patients treated with clozapine
    Ghaeli, P; Dufresne, RL
  • Ketoacidosis as a side effect of clozapine: A case study
    Kostakoglu, AE; Yazici, KM; Erbas, T
  • Clozapine and associated diabetes mellitus
    Popli, AP; Konicki, PE; Jurjus, GJ; Fuller, MA; Jaskiw, GE
  • Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study
    Henderson, DC; Cagliero, E; Gray, C; Nasrallah, RA; Hayden, DL; Schoenfeld, DA; Goff, DC
  • Novel antipsychotics and new onset diabetes
    Wirshing, DA; Spellberg, BJ; Erhart, SM; Marder, SR; Wirshing, WC
  • Hyperglycemia associated with olanzapine
    Fertig, MK; Brooks, VG; Shelton, PS; English, CW
  • Diabetic ketoacidosis with olanzapine treatment
    Gatta, B; Rigalleau; Gin, H
  • Olanzapine-induced ketoacidosis with diabetes mellitus
    Lindenmayer, J-P; Patel, R
  • New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment
    Goldstein, LE; Sporn, J; Brown, S; Kim, H; Finkelstein, J; Gaffey, GK; Sachs, G; Stern, TA
  • Different influences of classical antipsychotics and clozapine on glucoseinsulin homeostasis in patients with schizophrenia or related psychoses
    Melkersson, KI; Hulting, AL; Brismar, KE
  • Prevalence of diabetes and impaired glucose tolerance in patients treated with Clozapine compared with patients treated with conventional depot neuroleptic medications
    Hagg, S; Joelsson, L; Mjorndal, T; Spigset, O; Oja, G; Dahlqvist, R
  • The effect of clozapine on glucose metabolism
    Yazici, KM; Erbas, T; Yazici, AII
  • New-onset diabetes mellitus associated with the initiation of Quetiapine treatment
    Sobel, M; Jaggers, ED; Franz, MA
  • The effect of acute administration of risperidone on local cerebral glucose utilization in the rat
    Huang, YH; Tsai, SJ; Huang, HJ; Sim, CB
  • Schizophrenia and diabetes mellitus
    Mohan, D; Gordon, H; Hindley, N; Barker, A
  • Diabetes mellitus in schizophrenic patients
    Mukherjee, S; Decina, P; Bocola, V; Saraceni, F; Scapicchio, PL
  • Family history of type 2 diabetes in schizophrenic patients
    Mukherjee, S; Schnur, DB; Reddy, R
  • Schizophrenia: An extended etiological explanation
    Holden, RJ; Mooney, PA; Newman, JC
  • The dopamine hypothesis of schizophrenia: Focus on the dopamine receptor
    Snyder, SH
  • Glucose suppresses basal firing and haloperidol-induced increases in the firing rate of central dopaminergic neurons
    Saller, CF; Chiodo, LA
  • Glucose potentiates haloperidol-induced catalepsy
    Saller, CF; Kopin, IJ
  • Dopamine receptor binding is elevated in diabetic rats
    Lozovsky, D; Saller, CF; Kopin, IJ
  • Reduced anorexic and locomotor-stimulant action of D-amphetamine in alloxan-diabetic rats
    Marshall, JF; Friedman, MI; Heffner, TG
  • Further analysis of the resistance of the diabetic rat to d-amphetamine
    Marshall, JF
  • Potentiation of amphetamineinduced arousal by starvation
    Campbell, BA; Fibiger, HC
  • Possible association between tardive dyskinesia and altered carbohydrate metabolism
    Mukherjee, S; Wisniewski, A; Bilder, R; Sackheim, H
  • Persistent tardive dyskinesia and neuroleptic effects on glucose tolerance
    Mukherjee, S; Roth, SD; Sandyk, R; Schnur, DB
  • Tardive Dyskinesia
    Mukherjee, S; Mahadik, S
  • Risk of tardive dyskinesia in older patients
    Jeste, DV; Caliguiri, MP; Paulsen, JS; Heaton, RK; Lacro, JP; Harris, MJ; Bailey, A; Fell, RL; McAdams, LA
  • The prevalence of tardive dyskinesia in neuroleptic-treated diabetics. A controlled study
    Ganzini, L; Heintz, RT; Hoffman, WF; Casey, DE
  • Low dose insulin treatment of tardive dyskinesia: Conjuncture or conjecture
    Mouret, J; Khomais, M; Lemoine, P; Sebert, P
  • Neuroendocrine effects of haloperidol therapy in chronic schizophrenia
    Brambilla, F; Guerrini, A; Guastalla, A
  • Tardive dyskinesia and glucose metabolism
    Gillman, MA; Sandyk, R
  • Impaired glucose tolerance and abnormal movements in patients with schizophrenia
    Schultz, SK; Arndt, S; Ho, B-C; Oliver, SE; Andreasen, NC
  • Transport of glucose from blood to brain
    Lund-Andersen, H
  • Evidence for a family of transporterlike proteins. Sequence and gene localization of a protein expressed in fetal skeletal muscle and other tissues
    Kayano, T; Fukumoto, H; Eddy, RL; Fan, Y-S; Byers, MG; Shows, TB; Bell, GI
  • Family of glucose-transporter genes. Implications for glucose homeostasis and diabetes
    Mueckler, M
  • Mammalian facilitative glucose transporter family structure and molecular regulation
    Pessin, JE; Bell, GI
  • Expression of two glucose transporters,GLUT1 and GLUT3, in cultured cerebellar neurons: Evidence for neuron-specific expression of GLUT3
    Maher, F; Davies-Hill, TM; Lysko, PG; Henneberry, RC; Simpson, IA
  • Tissue distribution and species difference of the brain type glucose transporter (GLUT3)
    Yano, H; Seino, Y; Inagaki, N; Hinokio, Y; Yamamoto, T; Yasuda, K; Masuda, K; Someya, Y; Imura, H
  • Glucose transporters in brain: Delivery of glucose to neurons and glia
    Vannucci, SJ; Maher, F; Simpson, IA
  • Immunocytochemical localization of the insulin-responsive glucose transporter 4 (GLUT4) in the rat central nervous system
    El Messari, S; Leluop, C; Quignon, M; Brisorgueil, M-J; Penicaud, L; Arluison, M
  • Hexokinases
    Wilson, JE
  • Regulation of muscle carbohydrate metabolism during exercise
    Stanley, WC; Connett, RJ
  • Hormonal regulation of mammalian glucose transport
    Simpson, IA; Cushman, SW
  • Developmental expression of GLUT3 glucose transporter in the rat brain
    Nagamatsu, S; Sawa, H; Nakamichi, Y; Katahira, H; Inoue, N
  • Glucose transporter expression in brain: Relationship to cerebral glucose utilization
    Vannucci, SJ; Clark, RR; Koehler-Stec, E; Li, K; Smith, CB; Davies, P; Maher, F; Simpson, IA
  • Glucose transport and metabolism in the brain
    Robinson, PJ; Rapoport, SI
  • Brain glucose utilization and transport and cortical function in chronic vs. acute hypoglycemia
    Pelligrino, DA; Segil, LJ; Albrecht, RF
  • GLUT-1 deficiency syndrome caused by haploinsufficiency of the blood-brain barrier hexose carrier
    Seidner, G; Alvarez, M; Yeh, J-I; O'Driscoll, KR; Klepper, J; Stump, TS; Wang, D; Spinner, NB; Birnbaum, MJ; DeVivo, DC
  • Apparent biphasic effect of chlorpromazine on insulin release from isolated rat pancreatic islets
    Ammon, HP; Steinke, J
  • Effect of chlorpromazine (CPZ) on insulin release in vivo and in vitro in the rat
    Ammon, HP; Orci, L; Steinke, J
  • Basic and Clinical Pharmacology
    Hollister, LE
  • Effects of the 5-HT1C/ 5-HT2 receptor agonistsDOIand ®-methyl-5-HT on plasma glucose and insulin levels in the rat
    Chaouloff, F; Laude, D; Baudrie, V
  • Hyperglycemic properties of serotonin receptor antagonists
    Wozniak, KM; Linnoila, M
  • Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors
    Tecott, LH; Sun, LM; Akana, SF; Strack, AM; Lowenstein, DH; Dallman, MF; Julius, D
  • Action of phenothiazine derivatives on carbohydrate uptake of isolated rat diaphragm and isolated rat spinal cord
    Rafaelsen, OJ
  • Effects of psychotropic drugs on the erythrocyte permeability to glucose and ethylidene glucose
    Baker, GF; Rogers, HJ
  • Influence of various substances which induce and inhibit aggregation on the uptake of deoxyglucose by human blood platelets
    Gaut, ZN
  • Antipsychotic drugs affect glucose uptake and the expression of glucose transporters in PC12 cells
    Dwyer, DS; Pinkofsky, HB; Liu, Y; Bradley, RJ
  • Cytotoxic effects of neuroleptic drugs
    Munyon, WH; Salo, R; Briones, DF
  • Dopamine receptor antagonists modulate glucose uptake in rat pheochromocytoma (PC12) cells
    Dwyer, DS; Liu, Y; Bradley, RJ
  • Model of the 3-D structure of the GLUT3 glucose transporter and molecular dynamics simulation of glucose transport
    Dwyer, DS
  • The inhibition of GLUT1 glucose transport and cytochalasin B binding activity by tricyclic antidepressants
    Pinkofsky, HB; Dwyer, DS; Bradley, RJ
  • Effect of psychotropic drugs on the uptake of 3H-norepinehrine by tissues
    Axelrod, J; Whitby, LG; Hertting, G
  • Effect of drugs on the uptake and release of 3H-norepinephrine in the rat heart
    Axelrod, J; Hertting, G; Potter, L
  • Thioridazine and diabetes
    Price, WA; Giannini, AJ
  • Low dose raclopride spares the extrapyramidal system in rat brain from metabolic effects
    Tarazi, FI; Shirakawa, O; Tamminga, CA
  • Effects of haloperidol challenge on regional cerebral glucose utilization in normal human subjects
    Bartlett, EJ; Brodie, JD; Simkowitz, P; Dewey, SL; Rusinek, H; Wolf, AP; Fowler, JS; Volkow, ND; Smith, G; Wolkin, A; Cancro, R
  • The brain metabolic patterns of clozapine and fluphenazine-treated patients with schizophrenia during a continuous performance task
    Cohen, RM; Nordahl, TE; Semple, WE; Andreason, P; Litman, RE; Pickar, D
  • Effects of clozapine and thiothixene on glucose metabolic rate in schizophrenia
    Buchsbaum, MS; Potkin, SG; Marshall, JF; Lottenberg, S; Teng, C; Heh, CW; Tafalla, R; Reynolds, C; Abel, L; Plon, L; Bunney, WE
  • American Psychiatric Association Review of Psychiatry
    Berman, KF; Weinberger, DR
  • Positron-emission Tomography in Schizophrenia Research
    Buchsbaum, MS
  • Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia. Assessment with Xenon-133 single-photon emission computed tomography
    Andreasen, NC; Rezai, K; Alliger, R; Swayze, VW; Flaum, M; Kirchner, P; Cohen, G; O'Leary, DS
  • Abnormalities of cerebral blood flow distribution in patients with chronic schizophrenia
    Ingvar, DH; Franzen, G
  • Hypofrontality in schizophrenia: Distributed dysfunctional circuits in neuroleptic-naive patients
    Andreasen, NC; O'Leary, DS; Flaum, M; Nopoulos, P; Watkins, GL; Boles Ponto, LL; Hichwa, RD
  • Altered modulation of prefrontal and subcortical brain activity in newly diagnosed schizophrenia and schizophreniform disorder. A regional cerebral blood flow study
    Rubin, P; Holm, S; Friberg, L; Videbech, P; Andersen, HS; Bendsen, BB; Stromso, N; Larsen, JK; Lassen, NA; Hemmingsen, R
  • The resting and activation issue of hypofrontality: A single photon emission computed tomography study in neuroleptic-naive and neuroleptic-free schizophrenic female patients
    Parellada, E; Catafau, AM; Bernardo, M; Lomena, F; Catarineu, S; Gonzalez-Monclus, E
  • Hypofrontality in schizophrenia
    Gur, RC; Gur, RE
  • Brain metabolism in patients with schizophrenia before and after acute neuroleptic administration
    Volkow, ND; Brodie, JD; Wolf, AP; Angrist, B; Russell, J; Cancro, R
  • Resting cerebral glucose metabolism in first-episode and previously treated patients with schizophrenia relates to clinical features
    Gur, RE; Mozley, PD; Resnick, SM; Mozley, LH; Shtasel, DL; Gallacher, F; Arnold, SE; Karp, JS; Alavi, A; Reivich, M; Gur, RC
  • Temporal lobe metabolic differences in medication-free outpatients with schizophrenia via the PET-600
    Nordahl, TE; Kusubov, N; Carter, C; Salamat, S; Cummings, AM; O'shora-Celaya, L; Eberling, J; Robertson, L; Huesman, R; Jagust, W; Budinger, TF
  • Regional cerebral blood flow and negative/positive symptoms in 24 drug-naive schizophrenics
    Sabri, O; Erkwoh, R; Schreckenberger, M; Cremerius, U; Schulz, G; Dickmann, C; Kaiser, HJ; Steinmeyer, EM; Sass, H; Buell, U
  • Effect of a haloperidol challenge on regional brain metabolism in neuroleptic-responsive and nonresponsive schizophrenic patients
    Bartlett, EJ; Brodie, JD; Simkowitz, P; Schlosser, R; Dewey, SL; Lindenmayer, JP; Rusinek, H; Wolkin, A; Cancro, R; Schiffer, W